Puma Biotechnology
PBYI
128 hedge funds and large institutions have $364M invested in Puma Biotechnology in 2020 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 36 increasing their positions, 45 reducing their positions, and 23 closing their positions.
1.88% more ownership
Funds ownership: 89.15% → 91.03% (+1.9%)
4% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 23
0% more funds holding
Funds holding: 128 → 128 (0)
0% less capital invested
Capital invested by funds: $366M → $364M (-$1.47M)
20% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 45
35% less call options, than puts
Call options by funds: $2.16M | Put options by funds: $3.33M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$28.8M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$10.3M |
| 3 |
FAM
Fred Alger Management
New York
|
+$8.74M |
| 4 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$6.94M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$3.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.44M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.68M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$7.35M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.63M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$4.03M |
PBYI Hedge Fund Activity: Q3 2020 in Review
128 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q3 2020, worth a combined $364M — down 0.4% from $366M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new PBYI positions and 23 closed out — a net gain of 1 holder — while 36 added to existing stakes and 45 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $28.8M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $9.44M sold.
- 128 institutional investors held Puma Biotechnology (PBYI) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $364M of Puma Biotechnology stock for Q3 2020, down 0.4% quarter-over-quarter.
- 24 funds opened new Puma Biotechnology positions in Q3 2020 and 23 closed out, a net change of +1 holder.
- The largest Puma Biotechnology buyer in Q3 2020 was Deerfield Management, an estimated $28.8M added.
- The largest Puma Biotechnology seller in Q3 2020 was T. Rowe Price Associates, an estimated $9.44M sold.
Based on aggregated 13F filings for Q3 2020.